GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

Item
http://www.wikidata.org/entity/Q34547492
Filling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial EvidenceDPP4 in DiabetesA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyondBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingGlucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndromeIncretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition.Incretin-related drug therapy in heart failure.A review of gliptins for 2014.Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study)Oral delivery of biologics using drug-device combinations.Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes.
P2860

GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

Item
http://www.wikidata.org/entity/Q34547492
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
GLP-1 receptor agonists vs. DP ...... or preferable than the other?
@ast
GLP-1 receptor agonists vs. DP ...... or preferable than the other?
@en
GLP-1 receptor agonists vs. DP ...... or preferable than the other?
@nl
type
label
GLP-1 receptor agonists vs. DP ...... or preferable than the other?
@ast
GLP-1 receptor agonists vs. DP ...... or preferable than the other?
@en
GLP-1 receptor agonists vs. DP ...... or preferable than the other?
@nl
prefLabel
GLP-1 receptor agonists vs. DP ...... or preferable than the other?
@ast
GLP-1 receptor agonists vs. DP ...... or preferable than the other?
@en
GLP-1 receptor agonists vs. DP ...... or preferable than the other?
@nl
P1433
P1476
P2093
P275
P2860
P304
P31
P356
P433
P478
P5008
P577
P5875
P698
P921
P932
P356
P1433
P1476
GLP-1 receptor agonists vs. DP ...... or preferable than the other?
@en
P2093
P275
P2860
P304
P31
P356
P433
P478
P5008
P577
P5875
P698
P921
P932